ANAPTYSBIO, INC.

(ANAB)
  Rapport
Temps réel estimé Cboe BZX  -  18/05 15:53:51
20.43 USD   -2.23%
04/05AnaptysBio, Inc. annonce ses résultats pour le premier trimestre se terminant le 31 mars 2022
CI
27/04Anaptysbio, Inc. annonce des données de phase 1 positives pour Anb032 (agoniste anti-Btla) et fournit des mises à jour sur son pipeline
CI
22/03ANAPTYSBIO, INC. : Guggenheim passe à neutre sur le dossier
ZM
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteurAnalyses Zonebourse
Actualités dans d'autres langues sur ANAPTYSBIO, INC.
04/05ANAPTYSBIO, INC Management's Discussion and Analysis of Financial Condition and Result..
04/05AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
04/05AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
04/05AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
29/04ANAPTYSBIO, INC : Change in Directors or Principal Officers, Financial Statements and Exhi..
28/04Anaptysbio announces positive anb032 (anti-btla agonist) top-line phase 1 data and prov..
28/04ANAPTYSBIO : Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provi..
27/04ANAPTYSBIO, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
27/04AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Prov..
27/04Anaptysbio, Inc. Announces Positive Anb032 (Anti-Btla Agonist) Top-Line Phase 1 Data an..
22/03Anaptysbio appoints daniel faga as interim chief executive officer
21/03ANAPTYSBIO, INC : Change in Directors or Principal Officers (form 8-K)
21/03AnaptysBio Taps Former Mirati Therapeutics' COO as Interim CEO
21/03AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
21/03AnaptysBio, Inc. Announces Management Changes
21/03AnaptysBio, Inc. Announces Executive Changes
15/03AFTER HOURS WATCH LIST SCORECARD : Gtlb, anab, coup
15/03AnaptysBio to Halt Imsidolimab Development for Acne After Trial; Shares Sink in Pre-Mar..
14/03MT NEWSWIRES AFTER HOURS WATCH LIST : Gtlb, anab, coup
14/03AnaptysBio to Halt Imsidolimab Development for Acne After Trial; Shares Plunge 13% Afte..
14/03ANAPTYSBIO : Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe A..
14/03ANAPTYSBIO, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
14/03AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe ..
14/03AnaptysBio, Inc Reports Imsidolimab Acorn Phase 2 Clinical Trial Data in Moderate-To-Se..
08/03Anaptysbio announces fourth quarter and full year 2021 financial results and provides p..
07/03AnaptysBio Swings to Loss in Q4, Revenue Plunges; Shares Drop Pre-Bell
07/03ANAPTYSBIO : Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pi..
07/03ANAPTYSBIO, INC Management's Discussion and Analysis of Financial Condition and Result..
07/03AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
07/03AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 202..
07/03AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides P..
07/03AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides P..
02/02Tres ETFs en la nube
13/01TRANSCRIPT : AnaptysBio, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-..
05/01AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
2021AnaptysBio Files $300 Million Mixed Shelf
2021INSIDER SELL : Anaptysbio
2021Hexima Names New Chief Development Officer
2021ANAPTYSBIO, INC : Completion of Acquisition or Disposition of Assets (form 8-K)
2021Anaptysbio announces appointment of daniel faga to board of directors
2021ANAPTYSBIO, INC : Change in Directors or Principal Officers (form 8-K)
2021AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
2021AnaptysBio, Inc. Announces Appointment of Daniel Faga to Board of Directors
2021AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
2021AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
2021ANAPTYSBIO : Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data - Form ..
2021ANAPTYSBIO, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
2021AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
2021AnaptysBio, Inc. Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
2021AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates..
2021ANAPTYSBIO, INC Management's Discussion and Analysis of Financial Condition and Result..
2021AnaptysBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended S..
2021AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates
2021INSIDER SELL : Anaptysbio
2021ANAPTYSBIO : Agrees With Sagard Healthcare to Monetize Portion of Jemperli Royalties
2021ANAPTYSBIO, INC : Entry into a Material Definitive Agreement (form 8-K)
2021ANAPTYSBIO : Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Millio..
2021AnaptysBio Announces Agreement with Sagard Healthcare Royalty Partners
2021ANAPTYSBIO : Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pu..
2021ANAPTYSBIO, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
2021ANAPTYSBIO : Presents updated data from imsidolimab phase 2 gallop trial in generalized pu..
2021ANAPTYSBIO : Mid-Stage Trial Shows Imsidolimab Drug Candidate May Have Potential Against P..
2021ANAPTYSBIO : Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pu..
2021AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized P..
2021ANAPTYSBIO : Corporate Presentation September 2021
2021ANAPTYSBIO : to Participate in the H.C. Wainwright 23rd Annual Global Investment Conferenc..
2021SECTOR UPDATE : Health Care Stocks Discounted Wednesday
2021SECTOR UPDATE : Health Care Stocks Underperforming Market Wednesday
2021ANAPTYSBIO : Fda grants accelerated approval of jemperli (dostarlimab-gxly) for dmmr recur..
2021SECTOR UPDATE : Health Care Stocks Flat To Lower Premarket Wednesday
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures Slip as Fed Minutes Eyed
2021UPDATE : AnaptysBio Gets FDA's Accelerated Approval for Second Indication of GlaxoSmithKli..
2021ANAPTYSBIO : Receives FDA's Accelerated Approval for Second Indication of GlaxoSmithKline'..
2021AnaptysBio Up 10% on GSK Drug Indication Approval
2021FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Ad..
1  2  3  4  5Suiv.